相似文献
1
Author Correction: SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation.
Nat Struct Mol Biol. 2020 Nov;27(11):1094. doi: 10.1038/s41594-020-00533-x.
2
SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation.
Nat Struct Mol Biol. 2020 Oct;27(10):959-966. doi: 10.1038/s41594-020-0511-8. Epub 2020 Sep 9.
3
Middle East Respiratory Syndrome Coronavirus nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus while Sparing mRNAs of Cytoplasmic Origin.
J Virol. 2015 Nov;89(21):10970-81. doi: 10.1128/JVI.01352-15. Epub 2015 Aug 26.
4
Author Correction: Detection of SARS-CoV-2 in nasal swabs using MALDI-MS.
Nat Biotechnol. 2020 Oct;38(10):1211. doi: 10.1038/s41587-020-0701-2.
5
Author Correction: Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.
Nat Rev Immunol. 2020 Oct;20(10):644. doi: 10.1038/s41577-020-00430-w.
6
Author Correction: A stochastic agent-based model of the SARS-CoV-2 epidemic in France.
Nat Med. 2020 Nov;26(11):1801. doi: 10.1038/s41591-020-1129-4.
7
Author Correction: Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.
Nat Med. 2020 Sep;26(9):1494. doi: 10.1038/s41591-020-1058-2.
8
Author Correction: Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care.
Sci Rep. 2020 Aug 12;10(1):13892. doi: 10.1038/s41598-020-70939-6.
9
Author Correction: A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics.
Nat Commun. 2020 Sep 17;11(1):4793. doi: 10.1038/s41467-020-18720-1.
10
Author Correction: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Nat Commun. 2020 Oct 20;11(1):5409. doi: 10.1038/s41467-020-19339-y.
引用本文的文献
1
Coronavirus endoribonuclease nsp15 suppresses host protein synthesis and evades PKR-eIF2α-mediated translation shutoff to ensure viral protein synthesis.
PLoS Pathog. 2025 Mar 17;21(3):e1012987. doi: 10.1371/journal.ppat.1012987. eCollection 2025 Mar.
2
Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1.
Front Cell Infect Microbiol. 2024 Feb 5;14:1357866. doi: 10.3389/fcimb.2024.1357866. eCollection 2024.
3
SARS-CoV-2 and the DNA damage response.
J Gen Virol. 2023 Nov;104(11). doi: 10.1099/jgv.0.001918.
4
Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection.
Front Immunol. 2023 Apr 17;14:1156758. doi: 10.3389/fimmu.2023.1156758. eCollection 2023.
5
Cyclin D3 restricts SARS-CoV-2 envelope incorporation into virions and interferes with viral spread.
EMBO J. 2022 Nov 17;41(22):e111653. doi: 10.15252/embj.2022111653. Epub 2022 Oct 10.
6
Stability of SARS-CoV-2-Encoded Proteins and Their Antibody Levels Correlate with Interleukin 6 in COVID-19 Patients.
mSystems. 2022 Jun 28;7(3):e0005822. doi: 10.1128/msystems.00058-22. Epub 2022 May 18.
7
The key features of SARS-CoV-2 leader and NSP1 required for viral escape of NSP1-mediated repression.
RNA. 2022 May;28(5):766-779. doi: 10.1261/rna.079086.121. Epub 2022 Mar 1.
8
The N-terminal domain of SARS-CoV-2 nsp1 plays key roles in suppression of cellular gene expression and preservation of viral gene expression.
Cell Rep. 2021 Oct 19;37(3):109841. doi: 10.1016/j.celrep.2021.109841. Epub 2021 Sep 30.
9
SARS-CoV-2 NSP1 C-terminal (residues 131-180) is an intrinsically disordered region in isolation.
Curr Res Virol Sci. 2021;2:100007. doi: 10.1016/j.crviro.2021.100007. Epub 2021 Apr 5.
10
Diagnostic Utility of a Ferritin-to-Procalcitonin Ratio to Differentiate Patients With COVID-19 From Those With Bacterial Pneumonia: A Multicenter Study.
Open Forum Infect Dis. 2021 Mar 14;8(6):ofab124. doi: 10.1093/ofid/ofab124. eCollection 2021 Jun.
Zotero 插件